First, in vitro investigations provided by Sternberg et al. [45] on peripheral blood mononuclear cells (PBMCs) isolated from MS patients showed that luteolin dose-dependently reduced PBMCs proliferation as well as production of IL-1β, TNF-α, and matrix metalloproteinase-9 (MMP-9), the inflammatory factors that are crucial in MS. This evidence concerns the gene MMP9 and myeloid sarcoma.